CCA
KURA icon

Cygnus Capital Advisors’s Kura Oncology KURA Stock Holding History

Cygnus Capital Advisors’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,788
Closed -$15K – 90
2026
Q1 		$15K Hold
1,788
– – 0.01% 92
2025
Q4 		$19K Buy
+1,788
New +$18.8K 0.01% 72

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Cygnus Capital Advisors's KURA Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Kura Oncology (KURA) in Q2 2026, closing a stake of 1,788 shares — an estimated $15K sold.

Cygnus Capital Advisors first reported a position in KURA in Q4 2025 and held it in 2 quarters. The position peaked at $19K in Q4 2025. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Kura Oncology position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 1,788 Kura Oncology shares in Q2 2026, an estimated $15K.
  • Cygnus Capital Advisors first reported a position in Kura Oncology in Q4 2025 and held it in 2 quarters.
  • Cygnus Capital Advisors's Kura Oncology position peaked at $19K in Q4 2025.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.